Advertisement

Survey of laboratory-acquired infections around the world in biosafety level 3 and 4 laboratories

  • N. Wurtz
  • A. Papa
  • M. Hukic
  • A. Di Caro
  • I. Leparc-Goffart
  • E. Leroy
  • M. P. Landini
  • Z. Sekeyova
  • J. S. Dumler
  • D. Bădescu
  • N. Busquets
  • A. Calistri
  • C. Parolin
  • G. Palù
  • I. Christova
  • M. Maurin
  • B. La Scola
  • D. Raoult
Original Article

Abstract

Laboratory-acquired infections due to a variety of bacteria, viruses, parasites, and fungi have been described over the last century, and laboratory workers are at risk of exposure to these infectious agents. However, reporting laboratory-associated infections has been largely voluntary, and there is no way to determine the real number of people involved or to know the precise risks for workers. In this study, an international survey based on volunteering was conducted in biosafety level 3 and 4 laboratories to determine the number of laboratory-acquired infections and the possible underlying causes of these contaminations. The analysis of the survey reveals that laboratory-acquired infections have been infrequent and even rare in recent years, and human errors represent a very high percentage of the cases. Today, most risks from biological hazards can be reduced through the use of appropriate procedures and techniques, containment devices and facilities, and the training of personnel.

Keywords

Brucellosis Personal Protective Equipment Coccidioidomycosis Severe Acute Respiratory Syndrome Tularemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

We thank Robert A. Heinzen and Jean-Marc Reynes for their participation in the survey.

This study was supported by the projects APVV-0280-12 and VEGA 2/0005/15.

Compliance with ethical standards

Funding

None.

Ethical approval

Not applicable.

Informed consent

Not applicable.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Pike RM (1976) Laboratory-associated infections: summary and analysis of 3921 cases. Health Lab Sci 13:105–114PubMedGoogle Scholar
  2. 2.
    Harding LH, Byers KB (2006) Epidemiology of laboratory-acquired infections. In: Fleming DO, Hunt DL (eds) Biological safety: principles and practices, 4th edn. ASM Press, Washington, DCGoogle Scholar
  3. 3.
    Henkel RD, Miller T, Weyant RS (2012) Monitoring select agent theft, loss and release reports in the United States—2004–2010. Appl Biosafety 17:171–180CrossRefGoogle Scholar
  4. 4.
    Mattar ZR, Abugiazya A, Torok N, Assaly R (2009) Laboratory-acquired coccodioidmycosis. Chest 136:28SCrossRefGoogle Scholar
  5. 5.
    Kaye D (2005) Tularemia, laboratory acquired. Clin Infect Dis 40:3–4Google Scholar
  6. 6.
    Berkelman RL, Le Duc JW (2014) Culture of responsibility. Science 345:1101CrossRefPubMedGoogle Scholar
  7. 7.
    Normile D (2004) Infectious diseases. Mounting lab accidents raise SARS fears. Science 304:659–661CrossRefPubMedGoogle Scholar
  8. 8.
    Kaiser J (2014) The catalyst. Science 345:1112–1115CrossRefPubMedGoogle Scholar
  9. 9.
    Wurtz N, Grobusch MP, Raoult D (2014) Negative impact of laws regarding biosecurity and bioterrorism on real diseases. Clin Microbiol Infect 20:507–515CrossRefPubMedGoogle Scholar
  10. 10.
    Günther S, Feldmann H, Geisbert TW, Hensley LE, Rollin PE, Nichol ST et al (2011) Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 204:S785–S790Google Scholar
  11. 11.
    Next steps to enhance biosafety and biosecurity in the United States. October 29, 2015. Available online at: https://www.whitehouse.gov/sites/default/files/docs/10-2015_biosafety_and_biosecurity_memo.pdf
  12. 12.
    Centers for Disease Control and Prevention (CDC) (2014) Report on the potential exposure to anthrax. Available online at: http://www.cdc.gov/about/pdf/lab-safety/Final_Anthrax_Report.pdf
  13. 13.
    Arrêté du 30 juin 1998 modifiant l’arrêté du 18 juillet 1994 modifié fixant la liste des agents biologiques pathogènes (1998) Available online at: http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000000573056
  14. 14.
    Centers for Disease Control and Prevention (CDC) (2011) Fatal laboratory-acquired infection with an attenuated Yersinia pestis strain—Chicago, Illinois, 2009. MMWR Morb Mortal Wkly Rep 60:201–205Google Scholar
  15. 15.
    Barry M, Russi M, Armstrong L, Geller D, Tesh R, Dembry L et al (1995) Brief report: treatment of a laboratory-acquired Sabiá virus infection. N Engl J Med 333:294–296CrossRefPubMedGoogle Scholar
  16. 16.
    Vasconcelos PF, Travassos da Rosa AP, Rodrigues SG, Tesh R, Travassos da Rosa JF, Travassos da Rosa ES (1993) Laboratory-acquired human infection with SP H 114202 virus (Arenavirus: Arenaviridae family): clinical and laboratory aspects. Rev Inst Med Trop Sao Paulo 35:521–525PubMedGoogle Scholar
  17. 17.
    Formenty P, Hatz C, Le Guenno B, Stoll A, Rogenmoser P, Widmer A (1999) Human infection due to Ebola virus, subtype Côte d’Ivoire: clinical and biologic presentation. J Infect Dis 179:S48–S53CrossRefPubMedGoogle Scholar
  18. 18.
    Feldmann H (2010) Are we any closer to combating Ebola infections? Lancet 375:1850–1852CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Beer B, Kurth R, Bukreyev A (1999) Characteristics of Filoviridae: Marburg and Ebola viruses. Naturwissenschaften 86:8–17CrossRefPubMedGoogle Scholar
  20. 20.
    Nikiforov VV, Turovskiĭ I, Kalinin PP, Akinfeeva LA, Katkova LR, Barmin VS et al (1994) A case of a laboratory infection with Marburg fever. Zh Mikrobiol Epidemiol Immunobiol 3:104–106PubMedGoogle Scholar
  21. 21.
    Normile D (2004) Infectious diseases. Second lab accident fuels fears about SARS. Science 303:26CrossRefPubMedGoogle Scholar
  22. 22.
    Orellana C (2004) Laboratory-acquired SARS raises worries on biosafety. Lancet Infect Dis 4:64CrossRefPubMedGoogle Scholar
  23. 23.
    Lim PL, Kurup A, Gopalakrishna G, Chan KP, Wong CW, Ng LC et al (2004) Laboratory-acquired severe acute respiratory syndrome. N Engl J Med 350:1740–1745CrossRefPubMedGoogle Scholar
  24. 24.
    Centers for Disease Control and Prevention (CDC) (2002) Suspected cutaneous anthrax in a laboratory worker—Texas, 2002. JAMA 287:2356–2358Google Scholar
  25. 25.
    Traxler RM, Lehman MW, Bosserman EA, Guerra MA, Smith TL (2013) A literature review of laboratory-acquired brucellosis. J Clin Microbiol 51:3055–3062CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Centers for Disease Control and Prevention (CDC) (2000) Laboratory-acquired human glanders—Maryland, May 2000. MMWR Morb Mortal Wkly Rep 49:532–535Google Scholar
  27. 27.
    Srinivasan A, Kraus CN, DeShazer D, Becker PM, Dick JD, Spacek L et al (2001) Glanders in a military research microbiologist. N Engl J Med 345:256–258CrossRefPubMedGoogle Scholar
  28. 28.
    Schlech WF 3rd, Turchik JB, Westlake RE Jr, Klein GC, Band JD, Weaver RE (1981) Laboratory-acquired infection with Pseudomonas pseudomallei (melioidosis). N Engl J Med 305:1133–1135CrossRefPubMedGoogle Scholar
  29. 29.
    Janovská S, Pávková I, Reichelová M, Hubáleka M, Stulík J, Macela A (2007) Proteomic analysis of antibody response in a case of laboratory-acquired infection with Francisella tularensis subsp. tularensis. Folia Microbiol (Praha) 52:194–198CrossRefGoogle Scholar
  30. 30.
    Barry MA (2005) Report of pneumonic tularemia in three Boston University researchers. Boston Public Health CommissionGoogle Scholar
  31. 31.
    Lam ST, Sammons-Jackson W, Sherwood J, Ressner R (2012) Laboratory-acquired tularemia successfully treated with ciprofloxacin: a case report. Infect Dis Clin Pract 20:204–207CrossRefGoogle Scholar
  32. 32.
    Kawamata J, Yamanouchi T, Dohmae K, Miyamoto H, Takahaski M, Yamanishi K et al (1987) Control of laboratory acquired hemorrhagic fever with renal syndrome (HFRS) in Japan. Lab Anim Sci 37:431–436PubMedGoogle Scholar
  33. 33.
    Nielsen CF, Sethi V, Petroll AE, Kazmierczak J, Erickson BR, Nichol ST et al (2010) Seoul virus infection in a Wisconsin patient with recent travel to China, March 2009: first documented case in the Midwestern United States. Am J Trop Med Hyg 83:1266–1268CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Mulders MN, Reimerink JH, Koopmans MP, van Loon AM, van der Avoort HG (1997) Genetic analysis of wild-type poliovirus importation into The Netherlands (1979–1995). J Infect Dis 176:617–624CrossRefPubMedGoogle Scholar
  35. 35.
    Arrêté du 30 avril 2012 fixant la liste des micro-organismes et toxines prévue à l’article L. 5139-1 du code de la santé publique (2012) Available online at: http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000025837146&dateTexte=&categorieLien=id
  36. 36.
    Inglesby TV, O’Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E et al (2002) Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236–2252CrossRefPubMedGoogle Scholar
  37. 37.
    Klietmann WF, Ruoff KL (2001) Bioterrorism: implications for the clinical microbiologist. Clin Microbiol Rev 14:364–381CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Bhattacharjee Y (2011) Anthrax investigation. Army missed warning signs about alleged anthrax mailer. Science 332:27CrossRefPubMedGoogle Scholar
  39. 39.
    Independent review of the safety of UK facilities handling foot-and-mouth disease virus (2007) Available online at: http://webarchive.nationalarchives.gov.uk/20130822084033/http://www.defra.gov.uk/footandmouth/investigations/pdf/spratt_final.pdf
  40. 40.
    Trevan T (2015) Biological research: rethink biosafety. Nature 527:155–158CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • N. Wurtz
    • 1
  • A. Papa
    • 2
  • M. Hukic
    • 3
    • 4
  • A. Di Caro
    • 5
  • I. Leparc-Goffart
    • 6
  • E. Leroy
    • 7
    • 8
  • M. P. Landini
    • 9
  • Z. Sekeyova
    • 10
  • J. S. Dumler
    • 11
  • D. Bădescu
    • 12
  • N. Busquets
    • 13
  • A. Calistri
    • 14
  • C. Parolin
    • 14
  • G. Palù
    • 14
  • I. Christova
    • 15
  • M. Maurin
    • 16
  • B. La Scola
    • 1
  • D. Raoult
    • 1
  1. 1.URMITE, CNRS UMR 7278, IRD 198, Inserm 1095, Aix Marseille Université, IHU Méditerranée InfectionMarseilleFrance
  2. 2.Department of Microbiology, Medical SchoolAristotle University of ThessalonikiThessalonikiGreece
  3. 3.International Burch University of SarajevoSarajevoBosnia and Herzegovina
  4. 4.Department of Medical ScienceAcademy of Sciences and Arts of Bosnia and HerzegovinaSarajevoBosnia and Herzegovina
  5. 5.National Institute for Infectious Diseases L. SpallanzaniRomeItaly
  6. 6.ERRIT-IRBA, HIA Laveran, Centre National de Référence des ArbovirosesMarseilleFrance
  7. 7.Laboratoire MiVEGEC, UMR IRD 224 CNRS 5290 UMIMontpellier Cedex 5France
  8. 8.International Center for Medical Research of FrancevilleFrancevilleGabon
  9. 9.Unit of Clinical Microbiology, Regional Reference Centre for Microbiological Emergencies (CRREM)St Orsola-Malpighi University HospitalBolognaItaly
  10. 10.Institute of VirologySlovak Academy of SciencesBratislavaSlovak Republic
  11. 11.Departments of Pathology and Microbiology & ImmunologyUniversity of Maryland School of MedicineBaltimoreUSA
  12. 12.Cantacuzino National Institute of ResearchBucharestRomania
  13. 13.IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB)Campus de la Universitat Autònoma de BarcelonaBellaterraSpain
  14. 14.Department of Molecular MedicineUniversity of PadovaPadovaItaly
  15. 15.Department of MicrobiologyNational Center of Infectious and Parasitic DiseasesSofiaBulgaria
  16. 16.Centre National de Référence des Francisella, Laboratoire de Bactériologie, Département des Agents Infectieux, Institut de Biologie et Pathologie, Centre Hospitalier Universitaire de GrenobleUniversité Joseph FourierGrenobleFrance

Personalised recommendations